SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
SciSparc's majority-owned subsidiary NeuroThera Labs reported progress in the FDA-approved Phase IIb trial of SCI-110 for adult Tourette syndrome. The investigational product has been manufactured and cleared via European Qualified Person batch release, enabling shipment to sites; all three clinical sites (Yale, Hannover Medical School, Tel Aviv Sourasky) have completed initiation activities and enrollment is set to begin.
Key figures
- Drug Name
- SCI-110
- Phase Of Trial
- Phase IIb
- Clinical sites
- ["Yale Child Study Center at Yale School of Medicine","Hannover Medical School","Tel Aviv Sourasky Medical Center"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.